A 39-year-old man with type 1 diabetes mellitus is referred for consideration of insulin-pump
therapy because of poor glycemic control and episodes of severe hypoglycemia. Insulin …

Aim Continuous subcutaneous insulin infusion (CSII) is increasingly used in clinical practice
for the management of selected patients with Type 1 diabetes. Several cost‐effectiveness …

Insulin pumps have come of age. With their proliferation in medical practice, some guidance
is necessary for prospective and current prescribers to ensure their optimal and safe use …

Objective To compare the efficacy, safety, and cost utility of continuous subcutaneous insulin
infusion (CSII) with multiple daily injection (MDI) regimens during the first year following …

Background With the rapid development of technologies for type 1 diabetes, economic
evaluations are integral in guiding cost-effective clinical and policy decisions. We therefore …

Thirty years after its introduction, the use of continuous subcutaneous insulin infusion (CSII)
keeps increasing, especially among children and adolescents. The technique, when used …

Continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) reduces HbA1c
levels and hypoglycaemia in patients with type 1 diabetes mellitus (T1DM) compared with …

Background The risk of developing long-term complications of type 1 diabetes (T1D) is
related to glycaemic control and is reduced by the use of intensive insulin treatment …

Insulin pumps have come of age. With their proliferation in medical practices, some
guidance is necessary for prospective and current prescribers to ensure their optimal and …

Aims/hypothesis: Continuous subcutaneous insulin infusion (CSII) is an important treatment
option for type 1 diabetes patients unable to achieve adequate glycemic control with multiple …